Eli Lilly reported a 56% year-over-year revenue increase to $19.8 billion in Q1 fiscal 2026, driven by its Zepbound and Mounjaro products, which will soon be covered by Medicare. The company posted non-GAAP earnings per share of $8.55, a 156% jump from last year, and provided optimistic annual guidance of up to $85 billion in revenue and $37 in EPS. Institutional investors are showing strong buying interest, reflecting confidence in Eli Lilly's robust sales growth and earnings momentum. This combination of strong fundamentals and growing institutional demand suggests Eli Lilly shares could continue to rise, making it a compelling stock for diversified portfolios.
A bipartisan US congressional committee is investigating whether Merck, AbbVie, and three other major pharmaceutical companies conducted clinical trials in China that may have supported Chinese military capabilities. The inquiry focuses on due dilige...
Innovent Biologics and Eli Lilly have signed an agreement for Innovent to handle importation, marketing, distribution, and promotion of Lilly's breast cancer drug Verzenios (abemaciclib) in mainland China. Lilly will continue manufacturing and produc...
The FDA has selected seven companies, including Eli Lilly and Regeneron, for its new PreCheck pilot program aimed at accelerating regulatory review of new pharmaceutical manufacturing facilities in the U.S. This program allows the FDA to review facil...
